Back to Journals » Cancer Management and Research » Volume 5

New and emerging combination therapies for esophageal cancer

Authors Wiedmann M, Mössner J

Received 10 February 2013

Accepted for publication 12 April 2013

Published 27 June 2013 Volume 2013:5 Pages 133—146


Checked for plagiarism Yes

Review by Single anonymous peer review

Peer reviewer comments 4

Marcus W Wiedmann,1,2 Joachim Mössner2
1Department of Internal Medicine I, St Mary's Hospital, Berlin, Germany; 2Division of Gastroenterology and Rheumatology, Department of Medicine, Neurology and Dermatology, University Hospital of Leipzig, Leipzig, Germany

Abstract: Esophageal cancer comprises two different histological forms – squamous cell carcinoma (SCC) and adenocarcinoma (AC). While the incidence of AC has increased steeply in Western countries during the last few years, the incidence of SCC is fairly stable. Both forms differ in pathogenesis and response to chemotherapy and radiation therapy. Plenty of studies have evaluated new chemotherapy combination regimens in the neoadjuvant, adjuvant, and palliative setting. In addition, new radiation and chemoradiation protocols have been investigated. Finally, molecular-targeted therapy has been included in several new randomized prospective trials. Therefore, this review presents new data on this topic and critically discusses promising approaches towards a more effective treatment in a disease with a grim prognosis.

Keywords: chemotherapy, chemoradiation, molecular targeted therapy

Creative Commons License © 2013 The Author(s). This work is published and licensed by Dove Medical Press Limited. The full terms of this license are available at and incorporate the Creative Commons Attribution - Non Commercial (unported, v3.0) License. By accessing the work you hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. For permission for commercial use of this work, please see paragraphs 4.2 and 5 of our Terms.